SMAD2 and myocardial infarction: In summary, our present findings demonstrated that HADC6 deficiency resists ischemic injury by a reduction of TGF‐β1/Smad2/3 signalling activation, leading to decreased extracellular matrix production, which reduces cardiac fibrosis and dysfunction, providing a potential molecular target in the treatment of patients with MI.